236 related articles for article (PubMed ID: 37174094)
21. Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers.
Mody K; Kasi PM; Yang J; Surapaneni PK; Bekaii-Saab T; Ahn DH; Mahipal A; Sonbol MB; Starr JS; Roberts A; Nagy R; Lanman R; Borad MJ
JCO Precis Oncol; 2019 Dec; 3():1-9. PubMed ID: 35100741
[TBL] [Abstract][Full Text] [Related]
22. Emerging role of precision medicine in biliary tract cancers.
Bogenberger JM; DeLeon TT; Arora M; Ahn DH; Borad MJ
NPJ Precis Oncol; 2018; 2():21. PubMed ID: 30302397
[TBL] [Abstract][Full Text] [Related]
23. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
Berchuck JE; Facchinetti F; DiToro DF; Baiev I; Majeed U; Reyes S; Chen C; Zhang K; Sharman R; Uson Junior PLS; Maurer J; Shroff RT; Pritchard CC; Wu MJ; Catenacci DVT; Javle M; Friboulet L; Hollebecque A; Bardeesy N; Zhu AX; Lennerz JK; Tan B; Borad M; Parikh AR; Kiedrowski LA; Kelley RK; Mody K; Juric D; Goyal L
Ann Oncol; 2022 Dec; 33(12):1269-1283. PubMed ID: 36089135
[TBL] [Abstract][Full Text] [Related]
24. Current and emerging immunotherapeutic approaches for biliary tract cancers.
Yuan ZG; Zeng TM; Tao CJ
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
[TBL] [Abstract][Full Text] [Related]
25. Circulating Cell-Free DNA-Based Comprehensive Molecular Analysis of Biliary Tract Cancers Using Next-Generation Sequencing.
Csoma SL; Bedekovics J; Veres G; Árokszállási A; András C; Méhes G; Mokánszki A
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008396
[TBL] [Abstract][Full Text] [Related]
26. Cell of origin in biliary tract cancers and clinical implications.
Moeini A; Haber PK; Sia D
JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585
[TBL] [Abstract][Full Text] [Related]
27. A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
Aimar G; Paratore C; Zichi C; Marino D; Sperti E; Caglio A; Gamba T; De Vita F; Di Maio M
Explor Target Antitumor Ther; 2021; 2(5):448-464. PubMed ID: 36045702
[TBL] [Abstract][Full Text] [Related]
28. Treating Biliary Tract Cancers: New Targets and Therapies.
Ho J; Fiocco C; Spencer K
Drugs; 2022 Nov; 82(17):1629-1647. PubMed ID: 36441502
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer.
Yu H; Xu Y; Gao W; Li M; He J; Deng X; Xing W
Front Oncol; 2022; 12():930611. PubMed ID: 36072793
[TBL] [Abstract][Full Text] [Related]
30. Atezolizumab: an investigational agent for the treatment of biliary tract cancer.
Hack SP; Zhu AX
Expert Opin Investig Drugs; 2021 Oct; 30(10):1007-1015. PubMed ID: 34459336
[TBL] [Abstract][Full Text] [Related]
31. Targets for therapy in biliary tract cancers: the new horizon of personalized medicine.
Iyer P; Chen MH; Goyal L; Denlinger CS
Chin Clin Oncol; 2020 Feb; 9(1):7. PubMed ID: 32146818
[TBL] [Abstract][Full Text] [Related]
32. Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer.
Wang Y; Chen T; Li K; Mu W; Liu Z; Shi A; Liu J; Zhao W; Lian S; Huang S; Pan C; Zhang Z
Front Oncol; 2021; 11():777617. PubMed ID: 34778094
[TBL] [Abstract][Full Text] [Related]
33. Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.
Neuzillet C; Artru P; Assenat E; Edeline J; Adhoute X; Sabourin JC; Turpin A; Coriat R; Malka D
Target Oncol; 2023 Jan; 18(1):51-76. PubMed ID: 36745342
[TBL] [Abstract][Full Text] [Related]
34. PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
Ricci AD; Rizzo A; Bonucci C; Tober N; Palloni A; Mollica V; Maggio I; Deserti M; Tavolari S; Brandi G
Medicines (Basel); 2020 Aug; 7(9):. PubMed ID: 32878011
[TBL] [Abstract][Full Text] [Related]
35. HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer.
Kim H; Kim R; Kim HR; Jo H; Kim H; Ha SY; Park JO; Park YS; Kim ST
Front Oncol; 2022; 12():834104. PubMed ID: 35252005
[TBL] [Abstract][Full Text] [Related]
36. Nivolumab: an investigational agent for the treatment of biliary tract cancer.
Di Federico A; Rizzo A; Ricci AD; Frega G; Palloni A; Tavolari S; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):325-332. PubMed ID: 33307866
[No Abstract] [Full Text] [Related]
37. Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer: Adding New Flavors to the Pizza.
Queiroz MM; Lima NF; Biachi de Castria T
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046631
[TBL] [Abstract][Full Text] [Related]
38. Emerging molecular target antagonists for the treatment of biliary tract cancer.
Lombardi P; Marino D; Fenocchio E; Chilà G; Aglietta M; Leone F
Expert Opin Emerg Drugs; 2018 Mar; 23(1):63-75. PubMed ID: 29468924
[TBL] [Abstract][Full Text] [Related]
39. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas.
Augustin J; Gabignon C; Scriva A; Menu L; Calmel C; Scatton O; Paye F; Fléjou JF; Praz F; Cervera P; Wendum D
Virchows Arch; 2020 Jul; 477(1):33-45. PubMed ID: 32447492
[TBL] [Abstract][Full Text] [Related]
40. Current progress in perioperative chemotherapy for biliary tract cancer.
Ioka T; Shindo Y; Ueno M; Nagano H
Ann Gastroenterol Surg; 2023 Jul; 7(4):565-571. PubMed ID: 37416744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
